RT BSCN (@BSCNews)2025 TOKEN REVIEW: $ICP - A comprehensive insight into the token behind @dfinity's Internet Computer... https://t.co/5qXoOBzMXs ...

RT BSCN (@BSCNews)2025 TOKEN REVIEW: $ICP - A comprehensive insight into the token behind @dfinity's Internet Computer... https://t.co/5qXoOBzMXs ...

RT Santiment (@santimentfeed)🧑‍💻 Here are crypto's top overall coins by notable development activity the past 30 days. Directional indicators represent each project's rank rise or fall since last month:➡️ 1) @dfinity $ICP 🥇➡️ 2) @chainlink $LINK 🥈📈 3) @filecoin $FIL 🥉📉 4) @starknet $STRK📉 5) @cardano $ADA📈 6) @deepbookonsui $DEEP📈 7) @suinetwork $SUI📈 8) @avax $AVAX📉 T9) @polkadot $DOT📉 T9) @kusamanetwork $KSM📖 Read about the Santiment methodology for pulling github activity data from project repositories, ...

通信世界网消息（CWW）在全球电商竞争白热化与直播带货模式深度渗透的背景下，"出海"与"直 播"已成为中国电商企业寻求增长的关键路径。然而，跨国运营的复杂网络环境、海量用户涌入的瞬时 压力、日益严苛的安全合规要求以及AI技术深度融合带来的新挑战，正在倒逼云计算基础设施进行前 所未有的重构。近日，Akamai公司亚太与全球客户云架构总监李文涛与大中华区售前高级经理马俊向 媒体深入剖析了当前电商行业面临的核心技术挑战，并阐述了Akamai以"简而未减，网络先行，拥抱开 源"为核心理念打造的公有云如何提供针对性解决方案。 新需求：电商全球化的严苛技术考卷 在直播过程中，用户的交互体验关系着电商真金白银的收入，因此低延迟与高弹性已成为电商的生命 线。"页面加载延迟从1秒增至3秒，直播跳出率上升32%；资源加载时间缩短100毫秒，最终转化率则能 提升8.4%。"马俊以一组数字说明网络低时延的重要性。更具挑战的是，"双十一""6·18"等电商大促期 间，用户访问流量常常在短时间内出现爆发式增长，形成"脉冲式""尖刺式"模型。由于难以精准预测峰 值，商家往往过度配置资源以确保可靠性，造成局部节点过载并浪费资源成本。因此，降 ...

Valour Lists HBAR Staking ETP On SIX Swiss ExchangeETP issuer Valour has launched its first products on the SIX Swiss Exchange, listing staking ETPs for HBAR and ICP, providing regulated, transparent exposure with integrated native staking rewards for Swiss investors.These ETPs, already available on other European exchanges, enable access to protocol yields without wallet management.The launch expands Valour’s European footprint to over 75 ETPs as it moves toward its goal of 100 ETPs by the end of 2025.Sour ...

Core Insights - DeFi Technologies has successfully launched two digital asset exchange traded products (ETPs) on the SIX Swiss Exchange, marking its entry into the Swiss market [1][6] - The newly listed ETPs, 1Valour Hedera (HBAR) and 1Valour Internet Computer (ICP), provide regulated access to digital assets while integrating staking rewards [2][6] Product Details - 1Valour Hedera (HBAR) Physical Staking offers exposure to the Hedera network's native token, HBAR, while capturing staking rewards without requiring users to manage wallets [3] - 1Valour Internet Computer (ICP) Physical Staking provides passive exposure to ICP, enabling investors to participate in the network's native economics through a traditional financial instrument [4] Executive Commentary - Johanna Belitz, Head of Nordics and DACH at Valour, emphasized the significance of the launch on SIX as a milestone in democratizing access to digital assets in Switzerland [5] - Elaine Buehler, Head of Products at Valour, noted the growing institutional and retail appetite for yield-generating digital asset products [5] Market Expansion - With the addition of these products, Valour now offers over 75 ETPs across various European exchanges and aims to reach 100 ETPs by the end of 2025 [5][6]

2022年11月，OpenAI基于GPT 3.5推出了ChatGPT，短时间内便吸引了数千万用户，使大型语言模型 （LLM）正式走进公众视野，也将GPT架构推上了主流AI架构的宝座。随着ChatGPT打响大模型时代的 第一枪，各大厂商纷纷涌入这一赛道。由于ChatGPT无法直接接入国内，一些小作坊看到了套壳牟利的 机会，一时间，各种山寨ChatGPT在互联网上泛滥。 这些套壳行为最初往往不涉及任何二次开发，开发者只是简单地对API进行包装并出售。然而，随着监 管的加强，这种低劣的套壳手段很快就被打击。例如，"ChatGPT在线"公众号因涉嫌仿冒ChatGPT被罚 款6万元，成为首例"ChatGPT套壳"行政处罚案例。 尽管如此，套壳行为并未绝迹。在2023年发布的一些模型中，仍时常出现"GPT味"的回复，引发套壳质 疑。例如，讯飞星火大模型曾因涉嫌套壳ChatGPT而引发关注。对此，一些企业解释称，这可能是由于 训练数据中混入了大量ChatGPT生成的内容，导致模型"身份混淆"。另一种可能是，模型研发团队在微 调训练过程中主动使用了通过ChatGPT等OpenAI旗下模型构造的数据集，即所谓的"数据蒸馏"。 ...

Summary of Conference Call Records Company/Industry Involved - **Company**: 北方华创 (North Huachuang) - **Industry**: Semiconductor Equipment and Consumer Market Key Points and Arguments North Huachuang and Semiconductor Equipment Industry 1. North Huachuang is identified as a leading domestic semiconductor equipment manufacturer, benefiting from the upgrade of advanced process technology in the semiconductor industry [1] 2. The company has established domestic substitution capabilities for all semiconductor equipment except high-end EUV lithography machines, positioning it as a core player in the semiconductor industry chain [1] 3. The global semiconductor equipment sales to semiconductor product sales ratio has increased from 10.5% in 2014 to an expected 18.5% in 2024, indicating rising importance [1] 4. The share of China's semiconductor equipment market in the global market has grown from 13% in 2015 to an anticipated 42% in 2024 [1] 5. The import equipment share is projected to decline from 91.8% in 2015 to 67.6% in 2024, suggesting a significant shift towards domestic equipment [2] 6. North Huachuang's market share in the domestic semiconductor market is expected to double by 2025 compared to 2020 [2] 7. The company’s ICP products maintain a leading position domestically, while its CCP products have achieved full coverage in key applications [2] 8. Revenue growth predictions for 2025 include a 37% increase for scientific products and a 39% increase for performance products [2] 9. Risks for the company include technological development risks, geopolitical factors, human resources risks, market demand risks, and supply chain risks [3] Consumer Market Insights 1. The consumer market has shown a moderate recovery in 2024, with a cumulative year-on-year growth in the mid-single digits from January to May [4] 2. Consumer confidence has slightly improved but remains below the critical level of 100, indicating ongoing caution among consumers [4] 3. The second half of the year may see improved consumer sentiment if consumption-related policies are further refined and expanded [4] 4. Companies are expected to face pressure on profitability due to intense price competition driven by consumer demand for value [5] 5. A new consumer trend is emerging, driven by younger consumers seeking unique product experiences and social attributes [6] 6. The perception of brand premium is shifting towards rationality, with some categories experiencing a gradual shrinkage of brand premiums [6] 7. Companies are increasingly looking to expand into overseas markets due to saturation in domestic markets, particularly in sectors like dining, home appliances, and apparel [7][8] 8. The investment focus for the second half of the year includes essential goods and emerging sectors that align with new consumer trends [9] Policy and Market Dynamics 1. Recent high-level meetings have emphasized the need for a unified national market and the elimination of low-price competition, aiming to enhance product quality and phase out outdated production capacity [10][11] 2. The glass manufacturing sector is expected to see a significant reduction in production, which may lead to improved market conditions and price recovery [12] 3. The automotive sector is experiencing fluctuations in new vehicle sales, with expectations for increased promotional activities and new model launches in the second half of the year [13][14] 4. Recent policies in the pharmaceutical sector aim to enhance the pricing mechanisms for innovative drugs, potentially increasing the pricing flexibility for companies [15][16][17][18] Other Important but Possibly Overlooked Content 1. The consumer market is witnessing a shift towards emotional experiences in purchasing decisions, moving away from purely functional needs [6] 2. The potential for structural growth opportunities exists in niche markets that cater to emerging consumer trends [9] 3. The integration of commercial insurance and medical insurance directories is being clarified, which may impact the pharmaceutical market dynamics [18]

Policy Developments - The National Healthcare Security Administration reported that the basic medical insurance coverage rate in China remains stable at over 95%, with 1.32662 billion people insured by the end of 2024 [2] - The total income of the national basic medical insurance fund for 2024 is projected to be CNY 34,913.37 billion, while total expenditures are expected to be CNY 29,764.03 billion, resulting in a current balance of CNY 4,639.17 billion [2] - Since the establishment of the National Healthcare Security Administration in 2018, 835 new drugs have been added to the medical insurance drug list, with over 5,400 million CNY in sales from newly negotiated drugs between 2018 and 2024 [2] Drug and Device Approvals - Bayer's non-hormonal drug elinzanetant has been approved by the UK Medicines and Healthcare products Regulatory Agency for treating moderate to severe vasomotor symptoms related to menopause [5] - Innovent Biologics' new BCL2 inhibitor mesutoclax has received FDA approval to commence clinical trials for treating myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes [6] - Tianyu Co., Ltd.'s subsidiary has passed the review for ezetimibe raw materials by the National Medical Products Administration, pending GMP compliance inspection results for market launch [7] Capital Market Activities - Innostellar Biotherapeutics has signed a ten-year exclusive promotion agreement with Golden Age Health for the commercialization of its gene therapy candidate LX101 in mainland China [9] Earnings Disclosures - Da'an Gene anticipates a net loss of CNY 140 million to 200 million for the first half of 2025 [11] - Huahai Pharmaceutical expects a net profit decline of 40% to 50% year-on-year, projecting a profit range of CNY 374 million to 449 million [12] - KingMed Diagnostics forecasts a net loss of CNY 95 million to 65 million for the first half of 2025, representing a significant year-on-year decline [13] - Xinmai Medical projects a net profit of CNY 304 million to 361 million for the first half of 2025, a decrease of 10.52% to 24.78% compared to the previous year [14] - Wantai Biological Pharmacy anticipates a net loss of CNY 130 million to 160 million for the first half of 2025 due to market pressures and policy adjustments [15] Industry Events - *ST Suwu has received a notice of administrative penalty from the China Securities Regulatory Commission for falsifying financial reports, which may lead to forced delisting [17] - This incident serves as a warning for the pharmaceutical industry to focus on genuine innovation and establish effective internal controls to mitigate risks associated with management [17] Shareholder Movements - Qihe Venture, a shareholder holding over 5% of Xuantai Pharmaceutical, plans to reduce its stake by up to 7 million shares, representing no more than 1.5441% of the company's total shares [19]

Group 1 - The first ocean-level intelligent comprehensive scientific research vessel "Tongji" has been delivered, designed and built in China, featuring a 2000-ton capacity and multiple functionalities including marine geological, chemical, and biological research [1] - UBTECH's Tian Gong Walker robots have received over 100 orders, with expectations to deliver more than 300 units this year, indicating strong demand in the education and research sectors [2] - The first green hydrogen EPC project in Central Asia has successfully produced hydrogen, marking a significant breakthrough in large-scale industrial green hydrogen production [3] - The first phase of China's initial gravitational wave detection experiment has been completed, achieving its first light observation, which is a key step in the field of gravitational wave detection [4]